Showing results (141-150 of 1,273) with videos related to
Sort By:
Pageof 128
Clinical Colorectal Cancer|July 7, 2011
Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancerVikram K Jain, Eliza A Hawkes, David CunninghamClinical Colorectal Cancer|July 7, 2011
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancerClemens Giessen, Sebastian Stintzing, Ruediger Paul Laubender, et al.Clinical Colorectal Cancer|July 15, 2011
Prognostic significance of miR-215 in colon cancerMihriban Karaayvaz, Timothy Pal, Bo Song, et al.Clinical Colorectal Cancer|August 24, 2011
Multidisciplinary treatment of brain metastases derived from colorectal cancer incorporating stereotactic radiosurgery: analysis of 78 patientsEmmanouil Fokas, Martin Henzel, Klaus Hamm, et al.Clinical Colorectal Cancer|August 24, 2011
Prolonged oxaliplatin exposure alters intracellular calcium signaling: a new mechanism to explain oxaliplatin-associated peripheral neuropathyChristin Schulze, Margit McGowan, Sven-Eric Jordt, et al.Clinical Colorectal Cancer|August 9, 2011
Treatment advances in liver-limited metastatic colorectal cancerSteven R Alberts, Graeme J PostonClinical Colorectal Cancer|August 23, 2018
Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC TrialGabriel Glockzin, Florian Zeman, Roland S Croner, et al.Clinical Colorectal Cancer|August 29, 2018
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR StudyMarta Schirripa, Giuseppe Pasqualetti, Riccardo Giampieri, et al.Clinical Colorectal Cancer|August 29, 2018
Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal CancerNarikazu Boku, Shun YamamotoClinical Colorectal Cancer|April 29, 2018
Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal CancerTae Won Kim, Anneli Elme, Joon Oh Park, et al.Pageof 128